Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | PLEC | Q15149 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8758949 | 0.87 | MAPT (0.41) | SIRT6ADRB1MAPTALDH1A1SCN2A | |
| SCHEMBL4889720 | 0.87 | MAPT (0.41) | SIRT6ADRB1MAPTALDH1A1SCN2A | |
| SCHEMBL8758940 | 0.87 | MAPT (0.41) | SIRT6ADRB1MAPTALDH1A1SCN2A | |
| SCHEMBL4889710 | 0.87 | MAPT (0.41) | SIRT6ADRB1MAPTALDH1A1SCN2A | |
| SCHEMBL3382349 | 0.76 | SIRT6 (0.47) | SIRT6ADRB1MAPTPOLBALDH1A1 | |
| SCHEMBL3192879 | 0.74 | CFTR (0.39) | ADRB1 | |
| SCHEMBL2484091 | 0.72 | ALDH1A1 (0.45) | MAPTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL10929982 | 0.69 | MAPT (0.50) | SIRT6ADRB1MAPTPOLBALDH1A1 | |
| SCHEMBL13855677 | 0.69 | MAPT (0.50) | SIRT6ADRB1MAPTPOLBALDH1A1 | |
| SCHEMBL28030530 | 0.69 | SIRT6 (0.60) | SIRT6ADRB1MAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217022-B2 | Analogues of 1,3-bis(4-nitrophenyl)triazenes, their pharmaceutically acceptable salts and N-acyl derivatives for tumour treatment | RUDJER BOSKOVIC INSTITUTE (HR) | 2012-07-10 | — | — | US | disclosed |
| US-20110224412-A1 | Analogues Of 1,3-Bis(4-Nitrophenyl)Triazenes, Their Pharmaceutically Acceptable Salts And N-Acyl Derivatives For Tumour Treatment | RUDJER BOSKOVIC INSTITUTE (HR) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224412-A1 | Analogues Of 1,3-Bis(4-Nitrophenyl)Triazenes, Their Pharmaceutically Acceptable Salts And N-Acyl Derivatives For Tumour Treatment | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BAD | SIRT6 2692/4885ADRB1 1576/4885MAPT 3013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.